Japanese drug maker Taisho Pharmaceuticals’ type 2 diabetes drug luseogliflozin, which is sold under the brand name Lusefi in Japan, is proving to be an effective treatment for diabetic patients who consume a diet that is made up of 40 to 55 percent carbohydrates, according to a study published recently in the journal Diabetes, Obesity and Metabolism.
Luseogliflozin was approved by Japanese drug regulators in 2014 but is currently not sold in the United States. It is in a newer class of type 2 diabetes drugs known as SGLT2 inhibitors, which includes the brand name drugs Invokana and Invokamet.
The latest study, conducted at the Kansai Electric Power Research Institute in Kobe, Japan, examined the safety and efficacy of luseogliflozin under differing carbohydrate intake in patients with type 2 diabetes. Participants were randomized for two weeks in groups of high carbohydrate meals, high glycemic index meals, high carb/low glycemic index meals, and low carb meals. During this time, participants were given luseogliflozin and their glucose levels monitored. Researchers found that in all groups, patients experienced decreased blood sugar control.
Researchers concluded that luseogliflozin was effective in diabetic patients consuming a diet high in carbs. “But a strict low-carbohydrate diet on this class of drug should be avoided to prevent SGLT2 inhibitor-associated diabetic ketoacidosis,” the authors wrote.
Diabetic ketoacidosis, also called DKA, is a serious condition in which too much acid builds up in the blood. If left untreated, it can lead to diabetic coma or death. The condition is more common in type 1 diabetics, but type 2 diabetics taking SGLT2 inhibitors are at greater risk for developing ketoacidosis, the Food and Drug Administration (FDA) warned.
Source: Medical Xpress